Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments
Femasys Inc. (Nasdaq: FEMY) has received a second order from its Spanish distribution partners following successful commercial FemaSeed® infertility treatments in Europe. The Femasys team traveled to Madrid to train healthcare practitioners on the innovative procedure, which enhances natural fertilization by delivering sperm directly to the fallopian tube.
CEO Kathy-Lee Sepsick emphasized the importance of providing a lower-cost infertility treatment option, especially in the public sector where women often face long waits for IVF. Femasys recently announced strategic partnerships with Comercial Medico Quirurigca, SA (CMQ) for northern Spain and Durgalab for southern Spain to distribute FemaSeed and FemVue products.
Femasys Inc. (Nasdaq: FEMY) ha ricevuto un secondo ordine dai suoi partner di distribuzione spagnoli a seguito di trattamenti di infertilità FemaSeed® riusciti in Europa. Il team di Femasys si è recato a Madrid per formare i professionisti della salute sulla procedura innovativa, che migliora la fertilizzazione naturale consegnando direttamente lo spermatozoo nelle tube di Falloppio.
Il CEO Kathy-Lee Sepsick ha sottolineato l'importanza di offrire un'opzione di trattamento per l'infertilità a costo inferiore, soprattutto nel settore pubblico dove le donne spesso affrontano lunghe attese per la FIV. Femasys ha recentemente annunciato alleanze strategiche con Comercial Medico Quirurgica, SA (CMQ) per la Spagna settentrionale e Durgalab per quella meridionale per distribuire i prodotti FemaSeed e FemVue.
Femasys Inc. (Nasdaq: FEMY) ha recibido un segundo pedido de sus socios de distribución españoles tras el éxito de los tratamientos de infertilidad FemaSeed® en Europa. El equipo de Femasys viajó a Madrid para capacitar a los profesionales de la salud en el innovador procedimiento, que mejora la fertilización natural al entregar el esperma directamente en la trompa de Falopio.
La CEO Kathy-Lee Sepsick enfatizó la importancia de ofrecer una opción de tratamiento de infertilidad de bajo costo, especialmente en el sector público, donde las mujeres a menudo enfrentan largas esperas para la FIV. Femasys anunció recientemente asociaciones estratégicas con Comercial Medico Quirurgica, SA (CMQ) para el norte de España y Durgalab para el sur de España para distribuir los productos FemaSeed y FemVue.
Femasys Inc. (Nasdaq: FEMY)는 유럽에서 성공적인 FemaSeed® 불임 치료를 마친 후 스페인 유통 파트너들로부터 두 번째 주문을 받았습니다. Femasys 팀은 마드리드로 여행하여 혁신적인 절차에 대해 의료 제공자 교육을 실시했습니다. 이 절차는 정자를 난관에 직접 전달하여 자연 수정 능력을 향상시킵니다.
CEO Kathy-Lee Sepsick는 특히 여성들이 IVF를 위한 대기 시간이 긴 공공 부문에서 저비용 불임 치료 옵션을 제공하는 것의 중요성을 강조했습니다. Femasys는 최근 북부 스페인을 위한 Comercial Medico Quirurgica, SA (CMQ)와 남부 스페인을 위한 Durgalab와 전략적 파트너십을 발표하여 FemaSeed 및 FemVue 제품을 유통합니다.
Femasys Inc. (Nasdaq: FEMY) a reçu une deuxième commande de ses partenaires de distribution espagnols suite à des traitements d'infertilité FemaSeed® réussis en Europe. L'équipe de Femasys s'est rendue à Madrid pour former les professionnels de la santé sur la procédure innovante, qui améliore la fertilisation naturelle en livrant les spermatozoïdes directement dans la trompe de Fallope.
La PDG Kathy-Lee Sepsick a souligné l'importance d'offrir une option de traitement de l'infertilité à bas coût, en particulier dans le secteur public où les femmes font souvent face à de longues attentes pour la FIV. Femasys a récemment annoncé des partenariats stratégiques avec Comercial Medico Quirurgica, SA (CMQ) pour le nord de l'Espagne et Durgalab pour le sud de l'Espagne afin de distribuer les produits FemaSeed et FemVue.
Femasys Inc. (Nasdaq: FEMY) hat eine zweite Bestellung von seinen spanischen Vertriebspartnern erhalten, nachdem die FemaSeed® Unfruchtbarkeitsbehandlungen in Europa erfolgreich waren. Das Femasys-Team reiste nach Madrid, um medizinisches Fachpersonal über das innovative Verfahren zu schulen, das die natürliche Befruchtung verbessert, indem es die Spermien direkt in den Eileiter liefert.
CEO Kathy-Lee Sepsick betonte die Bedeutung, eine kostengünstigere Behandlungsoption für Unfruchtbarkeit anzubieten, insbesondere im öffentlichen Sektor, wo Frauen oft lange auf IVF warten müssen. Femasys kündigte kürzlich strategische Partnerschaften mit Comercial Medico Quirurgica, SA (CMQ) für Nordspanien und Durgalab für Südspanien an, um die Produkte FemaSeed und FemVue zu vertreiben.
- Received second order from Spanish distribution partners
- Successful completion of first commercial FemaSeed® procedures in Europe
- Expanding market presence in Spain through strategic partnerships
- None.
Insights
The successful completion of FemaSeed® procedures in Spain and the subsequent second order represent a positive step for Femasys. This demonstrates market acceptance and potential demand for their innovative infertility treatment. The FemaSeed technology, which delivers sperm directly to the fallopian tubes, offers a less invasive and potentially more cost-effective alternative to IVF.
The expansion into the European market through strategic partnerships with CMQ and Durgalab is a smart move, potentially accelerating Femasys' revenue growth and market penetration. The emphasis on addressing long wait times for IVF in public healthcare systems could position FemaSeed as an attractive option for both patients and healthcare providers.
However, investors should note that while this news is promising, it's still early in the commercialization process. The company's ability to scale operations, maintain product quality and navigate regulatory landscapes in different countries will be important for long-term success. Additionally, the impact on Femasys' financials may not be immediately significant given the company's current market cap of
ATLANTA, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that the Company has received its second order from its strategic distribution partners after successfully completing its first commercial FemaSeed® procedures in Europe. Members of the Femasys team traveled to Madrid to in-service healthcare practitioners on the innovative FemaSeed infertility treatment, designed to enhance natural fertilization by precisely delivering sperm into the fallopian tube where conception occurs.
“We are thrilled to receive another order from our distribution partners in Spain exemplifying their confidence after successful completion of FemaSeed treatment procedures,” stated Kathy-Lee Sepsick, Femasys CEO commented, “The need for a lower cost infertility treatment prior to in vitro fertilization is ever so important particularly in the public sector where women often have to wait years to receive an IVF. We are going to continue working tirelessly to provide our first-line solution to as many women in the U.S. and across the world as possible.”
Earlier in September, Femasys announced its strategic distribution partnerships for FemaSeed and FemVue in Spain. Comercial Medico Quirurigca, SA (CMQ) will distribute the products in northern Spain and Durgalab will distribute them in the south.
About Spanish Infertility Market
According to the European registries by the European Society of Human Reproduction and Embryology (ESHRE)1, Spain has the most in vitro fertilization (IVF) clinics with 244 facilities in Europe. Additionally, Spain ranks second in intrauterine (IUI) insemination cycles using husband sperm and holds the top position for IUI cycles using donor sperm.
About Femasys
Femasys is a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic solutions, including a lead revolutionary product candidate and FDA-cleared products. FemaSeed® Intratubal Insemination, an innovative infertility treatment designed to deliver sperm directly where conception occurs, is FDA-cleared and has received regulatory approval in Canada and Europe. FemBloc® permanent birth control in late-stage clinical development is the first and only non-surgical, in-office, permanent birth control method intended to be a safer option for women at substantially less cost than the long-standing surgical alternative. The Company has developed diagnostic products that are complementary for which it has achieved regulatory approvals to market in the U.S., Canada, Europe, and other ex-U.S. territories, and which are commercial-ready due to its in-house manufacturing capabilities. Its diagnostic products include FemVue® and FemVue® MINI for fallopian tube assessment by ultrasound, which can be used in conjunction with FemCath®, an intrauterine catheter for selective fallopian tube evaluation, and FemCerv®, an endocervical tissue sampler for cervical cancer diagnosis. Learn more at www.femasys.com, or follow us on X, Facebook and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to develop and advance our current product candidates and programs into, and successfully initiate, enroll and complete, clinical trials; the ability of our clinical trials to demonstrate safety and effectiveness of our product candidates and other positive results; estimates regarding the total addressable market for our products and product candidates; our ability to commercialize our products and product candidates, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.
Contacts:
Investors:
CORE IR
Matt Blazei
IR@femasys.com
Media:
CORE IR
Kati Waldenburg
Media@femasys.com
1 ART in Europe, 2019: results generated from European registries by ESHRE, Human Reproduction, 2023, 38(12), 2321–2338, https://doi.org/10.1093/humrep/dead197, October 17, 2023.
FAQ
What is the latest development for Femasys (FEMY) in Spain?
How is Femasys (FEMY) expanding its presence in the Spanish market?
What is the advantage of Femasys' (FEMY) FemaSeed® treatment?
Where did Femasys (FEMY) conduct training for its FemaSeed® procedure?
